- Speaker Presentation – Karen Bulock, Ph.D., Associate Director of Discovery at RXi Pharmaceuticals, will present preclinical in vivo data showing robust, dose dependent, long-lasting, target-specific silencing data with an sd-rxRNA compound targeting CTGF (connective tissue growth factor). Additional data demonstrating that CTGF silencing results in reduction of myofibroblasts and collagen deposition, downstream effects related to abrogation of scar formation, will also be presented.
- Poster: Development of an sd-rxRNA™ Based Therapy for Treatment of Fibrosis: Preclinical Development Abstract - Outlines the results of several sd-rxRNA compounds targeting CTGF for the reduction of dermal scarring. Preclinical results using intradermal injection of CTGF targeting sd-rxRNAs show strong silencing for more than a week, as well as downstream effects related to abrogation of scar formation. RXi has initiated a preclinical development program for RXI-109, an sd-rxRNA compound designed to reduce the expression of CTGF, with a goal of submitting an IND in the second half of 2011.
- Poster: Self-Delivering RNAi Compounds (sd-rxRNA™) Demonstrate Robust Efficacy in vitro and in vivo in the Eye – Describes the preclinical studies used to establish the general utility of sd-rxRNA as a potential treatment for ocular disease. Data from these studies show that sd-rxRNA compounds not only successfully distribute to retinal cells without a delivery vehicle after an intravitreal injection, but also maintain statistically significant silencing of the mRNA target for up to 21 days. In addition, a pilot safety evaluation in mouse reveals no overt morphological, functional or microscopic signs of ocular toxicity.
- Poster: A Novel Class of Self-Delivering RNAi Compounds (sd-rxRNA™) with Robust in vitro and in vivo Efficacy: Mechanism of Action – Describes the development of a novel class of “self-delivering” RNAi (sd-rxRNA) compounds which demonstrate robust cellular uptake and silencing of target genes without the requirement for a delivery vehicle. sd-rxRNAs combine features of conventional RNAi and antisense technology and are heavily chemically modified to improve stability and lipophilicity. Preclinical data demonstrating the mechanism of uptake as well as efficacy of sd-rxRNA compounds using local and systemic administration in vivo will be presented.
RXi Pharmaceuticals Presents New Preclinical RNAi Data At The Keystone Mechanism And Biology Of Silencing Conference
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.